ArticleBriefings in bioinformatics2024
The mathematical exploration for the mechanism of lung adenocarcinoma formation and progression.
Article in Briefings in bioinformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Beyond metaphor: quantitative reconstruction of Waddington landscape and exploration of cellular behavior.Briefings in bioinformatics · 2025Review
- The YY1-ABCB7 regulatory Axis is associated with malignant progression and ferroptosis sensitivity in lung adenocarcinoma.Journal of molecular histology · 2025Article
- Expression of PSMD14 in lung adenocarcinoma and its impact on immune cell infiltration and prognosis: a comprehensive analysis based on RNA and single-cell RNA sequencing.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma, a prevalent subtype of lung cancer, represents one of the most lethal human malignancies. Despite substantial efforts to elucidate its biological underpinnings, the underlying mechanisms governing lung adenocarcinoma remain enigmatic. Modeling and comprehending the dynamics of gene regulatory networks are crucial for unraveling the fundamental mechanisms of lung adenocarcinoma. Conventionally, the cancer is modeled as an equilibrium process based on a time-invariant gene regulatory network to investigate stable cell states. However, the cancer is a nonequilibrium process and the gene regulatory network should be regarded as time-varying in actual. Therefore, a feasible framework was developed to explore the formation and progression of lung adenocarcinoma. On the one hand, to delve into the underlying mechanisms of lung adenocarcinoma formation, the time-invariant gene regulatory network for lung adenocarcinoma was initially undertaken, and the composition of stable cell states was elucidated based on landscape theory. Furthermore, the plasticity of different states was quantified using energy landscape decomposition theory by incorporating cell proliferation. And transition probabilities between different states were defined to elucidate the transition between stable cell states. Additionally, the global sensitivity analysis was performed and a total of three genes and three regulations were identified to be more critical for the formation lung adenocarcinoma, offering a novel strategy for designing network-based therapies for its treatment. On the other hand, the time-invariant gene regulatory network is extended as time-varying to delve into the underlying mechanisms of lung adenocarcinoma progression. The lung adenocarcinoma progression was characterized as four different disease stages based on the mixed states of cell population and the evolutionary direction. And the progressionary mechanism of transition between stages was expounded by evaluating their dynamical transport, with the dynamical transport cost between different stages quantified using Wasserstein metrics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.